Related Experiment Videos
Improvement following interferon-alpha 2A in chronic inflammatory demyelinating polyneuropathy
K C Gorson1, G Allam, D Simovic
1Neurology Service, St. Elizabeth's Medical Center, Boston, MA 02135, USA.
Neurology
|March 1, 1997
Summary
Interferon-alpha 2A shows promise for treating chronic inflammatory demyelinating polyneuropathy (CIDP) in patients refractory to standard therapies. This immune-mediated neuropathy may benefit from novel treatments like interferon-alpha when conventional options fail.
Area of Science:
- Neurology
- Immunology
- Clinical Therapeutics
Background:
- Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated disorder affecting peripheral nerves.
- Standard treatments include plasma exchange, intravenous immunoglobulin, and steroids.
- Some CIDP patients are refractory to these conventional therapies, necessitating alternative treatment strategies.